Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04947527Phase 2Completed

Efficacy and Safety Evaluation of Anti-Caries Varnish

Role: lead

NCT05670743Phase 2Completed

Pharmacokinetics of Advantage Arrest in Healthy Children 13-Months to 13-Years of Age

Role: lead

NCT05395065Completed

Silver Diamine Fluoride Gel: Case Series

Role: lead

NCT04186663Phase 2Completed

Pharmacokinetics of Advantage Arrest in Children

Role: lead

NCT04184271Phase 2Completed

Pharmacokinetics of Advantage Arrest

Role: lead

NCT04183231Phase 2Completed

Pharmacokinetics of Advantage Anti-Caries Varnish

Role: lead

All 6 trials loaded